Rotavirus vaccines, Rotarix and RotaTeq, are increasingly being introduced in national immunization programmes in Africa to prevent severe dehydrating acute gastroenteritis. A low-level risk of intussusception has been associated with rotavirus vaccines. We reviewed published data on intussusception in children <2 years of age in Africa. PubMed electronic database search was used to retrieve papers published on intussusception. The search was further refined to identify surveillance reports and case series conducted from 1980 to 2014, with at least 25 cases. The initial search identified 34 studies, and the refined search yielded 16. Intussusception occurred naturally in infants 2-4 months and peaked around 5-8 months of age. Delayed presentation was common and required surgical intervention in 87% (1008 of 1158) of cases with a high CFR, 10-33.7%. In African children, intussusception has been reported infrequently at a young age when the first dose of rotavirus vaccine is administered.
there is paucity of baseline data on intussusception epidemiology in Africa [4] [5] [6] [7] [8] .
In 1998, the first rotavirus vaccine, RotaShield (Wyeth Lederle Vaccines, Philadelphia), was approved and licensed in the USA and recommended for all infants as part of their routine immunization schedule. In July 1999, the US Centers for Disease Control and Prevention reported 15 cases of intussusception in recipients of the RotaShield vaccine, and the vaccine was withdrawn from the market [1, [9] [10] [11] [12] [13] . Further studies estimated an excess of one case of intussusception per 10 000 vaccinated children [14] .
The current vaccines, Rotarix (GlaxoSmithKline Biologicals) and RotaTeq (Merck Vaccines), are prequalified by the World Health Organization (WHO) and are rapidly being introduced in the Expanded Programme on Immunization (EPI) in Africa with the assistance from GAVI, the Vaccine Alliance. Both vaccines were effective and safe in clinical trials, but post-marketing evaluations have identified a lowlevel risk of one to six cases of intussusception per 100 000 vaccinated children [15] [16] [17] [18] . However, the benefits of rotavirus vaccine in terms of number of diarrhoea deaths and hospitalizations prevented substantially outweigh the low risk of intussusception in countries such as Brazil, Mexico, Australia, and the USA where both risk and benefit data are available [15] , and recommendations for vaccination remain unchanged.
WHO initially recommended that rotavirus vaccine should be introduced into national immunization programmes, with the first dose given between 6 and 15 weeks of age [3] , especially in countries with high disease burden and fatality rates in sub-Saharan Africa and south-eastern Asia [3, [19] [20] [21] . As of September 2015, 27 countries in the WHO African region had introduced rotavirus vaccine in their national immunization programmes. The maximum age for administering the last dose of rotavirus vaccine was initially recommend as 32 weeks [22] . In 2012, WHO relaxed its age recommendation to extend the benefits of vaccination to all children, even those who present late for vaccination, based on benefit versus risk considerations [23] . Background cases of intussusception, not related to rotavirus vaccination, will occur by chance alone among infants around the time when they receive the vaccine [22, 23] . Thus, it is important to gather baseline data on intussusception from countries introducing vaccine, particularly in the African region where available information is sparse.
In this review article, we summarize intussusception surveillance reports and case series conducted in Africa to describe the epidemiology of intussusception in young children before the introduction of the new oral rotavirus vaccines. Our data will help countries interpret data from post-marketing safety surveillance for oral rotavirus vaccines.
M E T H O D S
The search strategy used was the PubMed electronic database search-Medical Subject Headings. The search heading was 'intussusception', category or subheading 'epidemiology' and search builder 'Africa'. Additional search filters were 'age' birth to 23 months, 'custom date range' 1980 to 2014 and 'language' English and French. Identified reports were reviewed to select those that were surveillance reports or case series describing the epidemiology of intussusception cases. To ensure stability in proportions of key characteristics of interest and reduce ascertainment bias, the search was further refined by including only those reports with at least 25 children <2 years of age with intussusception from countries in the WHO African region. In some papers, incidence of intussusception in the children <2 years of age was calculated based on the data in the surveillance reports and case series.
R E S U L T S
After the initial search for intussusception in young children in Africa, 56 published reports were retrieved and 34 described the epidemiology of intussusception. Twenty-two reports were excluded, which included papers describing surgical procedures and diagnostic techniques. Further inclusion criteria of at least 25 children <2 years of age in the study resulted in 16 publications included in the analyses (Fig. 1) . Of these 16 studies, 13 were retrospective and three studies were prospective (Table 1) . Seven (43.8%) studies were from Nigeria. The South African study had the largest number of cases of intussusception (346), followed by the Zambian study with 105 cases (Table 1) .
In the reviewed studies, 1158 cases of intussusception were reported and >87% (1008 of 1158) underwent surgery for intussusception. A greater proportion of cases occurred in males than females. The majority of children <2 years with intussusception were infants <12 months of age and ranged from 61.5% in South Africa to 100% in Kenya, Nigeria and Zambia (Table 1 ). The case fatality rate (CRF) ranged from <2% in South Africa to 33.7% in Zambia, with a mean of 16.0% for all countries (Table  1) . Presentation for treatment was often delayed, with most surveillance studies indicating >3 days between onset and treatment (Table 1) , which was mainly surgical intervention ( Table 2 ). The peak age for intussusception was 5-8 months, but small numbers of cases were reported outside of this age range. In the two studies that calculated in crude incidence rates of intussusception, incidence ranged from 31 of 100 000 children <2 years of age in South Africa to 61 of 100 000 children <2 years of age in Zambia.
D I S C U S S I O N
Before rotavirus vaccine introduction, 16 papers describing the epidemiology of intussusception in children <2 years of age have been published from 11 countries in Africa, with 43.8% of studies being from Nigeria. Most of the studies were retrospective, with only two countries, Tanzania and Zambia, having prospective studies. There is limited data on the background crude incidence rates of intussusception in Africa. This ranged from 31 of 100 000 children <2 years of age in South Africa [24] to 61 of 100 000 children <2 years of age in Zambia [5] . However, in Western countries it is estimated at 66-120 per 100 000 infants, with the highest rates reported from South East Asia at >418 of 100 000 infants in China, Suzhon province [1, 6] . A more recent global review of childhood intussusception shows high incidence rates of intussusception of 302 of 100 000 in Vietnam and 328 of 100 000 in South Korea (4) .
In this review, 1158 infants and toddlers were diagnosed with intussusception. The CFR was as high as 28-34% [5, 7] . In all the studies, the high CFR was attributed to delayed presentation and late diagnosis in hospital [5, 7, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Delayed intervention in intussusception compromises both the anatomical and physiological viability of the affected intestine, leading to complications like bowel necrosis, wet gangrene and perforation with peritonitis and septicaemia, which require bowel resection. This contrasts sharply with lower mortality rates in developed countries of <1%, where children generally present for treatment early [1, 6] .
Additionally, the diagnosis of intussusception is made at surgery in Africa, as diagnostic facilities and qualified personnel for radiologic diagnosis are not readily available [36, 37] . Although there has been changes in diagnostic modalities in most regions of the world, this is not so in sub-Saharan Africa, as diagnosis has remained largely clinical and at surgery ( Table 2) . As delayed presentation and delayed diagnosis in hospitals is common in sub-Saharan Africa, less invasive treatment procedures such as air or hydrostatic reduction enema may not be an option, and thus, surgical intervention was the main stay of treatment (87%) [5, 21, 24, 26, 30, 31, [33] [34] [35] [36] [37] [38] . We were unable to distinguish from the papers reviewed between urban and rural in terms of outcome and surgical intervention. Hospitals with surgical suites for children are found in large urban teaching hospitals than rural district hospitals, which have no doctors with expertise to operate on infants and young 97% of patients had surgery and 3% had Barium enema toddlers <2 years. A study in South Africa showed that the underprivileged children in communities are more likely to present late in the disease and required invasive surgical intervention [35] . In many settings in Africa, bloody diarrhoea, a symptom of intussusception, is usually diagnosed as dysentery and treated as such, thus further delaying the diagnosis and intervention for intussusception in hospitals [5] . However, in young infants, bloody diarrhoea is less likely due to dysentery, and intussusception should be investigated. It is anticipated that with increasing awareness of health workers particularly in district hospitals and rural health facilities, more infants with intussusception will be recognized and referred early though the limiting factor will be access to centres with the necessary expertise to treat these patients [37] .
Based on the reports reviewed, the peak incidence for natural intussusception in Africa was 5-8 months of age. However, some cases occur in the younger age group of 3-5 months and are of particular concern, as this age group coincides with the age for administration of the oral rotavirus vaccine [3, 5, 39] . Background cases of intussusception (unrelated to vaccination) occur naturally among infants around the time when they receive rotavirus vaccine. This makes interpretation of temporal association of intussusception and receipt of rotavirus vaccine rather difficult [3] and needs to be interpreted cautiously, as misinterpretation of the data has the potential to undermine the whole immunization programme in Africa. In Africa, rotavirus vaccine is given at 6 and 10 weeks (monovalent, Rotarix) and 6, 10 and 14 weeks (Pentavalent, Rotateq), and so, if given on time, background rates of intussusception are likely to be low. However, it is well recognized that timeliness of immunization in Africa is a major concern, as a significant number of infants are immunized outside the recommended schedule, and this is more significant in the rural areas than urban areas [40, 41] .
The current era of rotavirus vaccine utilization calls for prospective intussusception surveillance as more countries in Africa are increasingly introducing rotavirus vaccines in their immunization programmes with GAVI support (Fig. 2) . Of the 47 countries in the WHO African region, 27 (57%) have already introduced oral rotavirus vaccine in their EPI programmes (as of September 2015), and this number is ever increasing every year [42] . It may not be possible for individual countries, some with small birth cohorts, to have a sufficient sample size to identify a small increased risk of intussusception following oral rotavirus vaccination. The African Intussusception Surveillance Network has been formed with the main objective of monitoring the safety of rotavirus vaccines under routine public health use among infants in countries introducing new oral rotavirus vaccines by assessing for any potential association between oral rotavirus vaccines and intussusception using the self-controlled case-series method [43] [44] [45] . Currently, 11 of 27 countries that have introduced rotavirus vaccines in EPI are monitoring intussusception using a standardized protocol. 
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